Literature DB >> 20919529

The role of PET scanning in pancreatic cancer.

Oscar K Serrano1, Muhammad A Chaudhry, Steven D Leach.   

Abstract

The strength of functional imaging lies in its ability to detect malignant disease irrespective of lesion morphology. In this setting, 18FDG-PET can complement management by providing a more accurate diagnosis. When combined as an adjunct to CT, 18FDG-PET can increase the sensitivity, specificity, and accuracy for detecting a pancreatic malignancy, especially in patients in whom CT alone fails to identify a discrete mass or in whom biopsy results are indeterminate. This capability is accentuated with small lesions of the pancreas. 18FDG-PET is significantly more sensitive in detecting metastatic disease than conventional CT imaging. Moreover, 18FDG-PET is able to differentiate tumor response to therapy in the postoperative setting, and could potentially serve to monitor recurrence patterns in the setting of neoadjuvant or adjuvant chemoradiotherapy. Finally, as 18FDG-PET/CT fusion modalities become more widespread and technical advances in image acquisition progress, 18FDG-PET will continue to have an increasing role in the diagnosis, staging, and surveillance of pancreatic cancer, integrating anatomic information with functional imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20919529     DOI: 10.1016/j.yasu.2010.05.007

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  9 in total

1.  Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

Authors:  Saiyin Hexige; Christine M Ardito-Abraham; Yanhua Wu; Youheng Wei; Yuan Fang; Xu Han; Jianang Li; Ping Zhou; Qing Yi; Anirban Maitra; Jun O Liu; David A Tuveson; Wenhui Lou; Long Yu
Journal:  J Pathol       Date:  2015-02-17       Impact factor: 7.996

Review 2.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

Review 4.  Diagnostic strategies for early pancreatic cancer.

Authors:  Keiji Hanada; Akihito Okazaki; Naomichi Hirano; Yoshihiro Izumi; Yuji Teraoka; Juri Ikemoto; Kozue Kanemitsu; Fumiaki Hino; Toshikatsu Fukuda; Shuji Yonehara
Journal:  J Gastroenterol       Date:  2014-12-14       Impact factor: 7.527

5.  Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Authors:  Joseph M Herman; Aaron T Wild; Hao Wang; Phuoc T Tran; Kenneth J Chang; Gretchen E Taylor; Ross C Donehower; Timothy M Pawlik; Mark A Ziegler; Hongyan Cai; Dionne T Savage; Marcia I Canto; Jason Klapman; Tony Reid; Raj J Shah; Sarah E Hoffe; Alexander Rosemurgy; Christopher L Wolfgang; Daniel A Laheru
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

6.  Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.

Authors:  Jose M Pimiento; Ashley H Davis-Yadley; Richard D Kim; Dung-Tsa Chen; Edward A Eikman; Claudia G Berman; Mokenge P Malafa
Journal:  Clin Nucl Med       Date:  2016-03       Impact factor: 7.794

Review 7.  Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.

Authors:  Gabriela Kramer-Marek; Jesse Gore; Murray Korc
Journal:  Cancer Lett       Date:  2013-08-11       Impact factor: 8.679

Review 8.  Molecular Imaging of Pancreatic Cancer with Antibodies.

Authors:  Christopher G England; Reinier Hernandez; Savo Bou Zein Eddine; Weibo Cai
Journal:  Mol Pharm       Date:  2015-12-10       Impact factor: 4.939

9.  The physiological characteristics of the basal microvilli microvessels in pancreatic cancers.

Authors:  Lixiang Ma; Xu Han; Jichun Gu; Ji Li; Wenhui Lou; Chen Jin; Hexige Saiyin
Journal:  Cancer Med       Date:  2020-06-02       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.